United States

This archive collects solutions-journalism stories and milestones from the United States — covering policy wins, community-led efforts, scientific advances, and social progress happening across the country. Each entry highlights what’s working and why it matters.

Vials and syringes in a lab, for article on not-for-profit drug access

Pfizer to sell all its drugs in 45 low-income countries at non-profit price

Pfizer’s not-for-profit pricing pledge now spans all 500 of its medicines — including chemotherapy and oral cancer treatments — across 45 of the world’s lowest-income countries. That’s a major expansion of an accord the company launched in 2022, which originally covered only patented drugs. By including off-patent medicines too, Pfizer is acknowledging that even decades-old cancer treatments often remain out of reach where generic supply chains never took hold. For patients across much of sub-Saharan Africa and South Asia, where cancer and heart disease are rising fast, this could quietly move the floor on what’s possible. And when the world’s largest drugmaker makes a move this broad, the rest of the industry tends to notice.

Cannabis being weighed, for article on legal cannabis dispensary, for article on Germany cannabis legalization

New York opens its first legal recreational cannabis dispensary

New York’s first legal recreational cannabis dispensary opened with a meaningful twist: the very first retail license went to Housing Works, a nonprofit that serves people with HIV, homeless New Yorkers, and the formerly incarcerated. Revenue from the shop will flow back into those social services, turning a newly legal market into direct support for communities hit hardest by the war on drugs. New York reserved its earliest licenses for nonprofits, people with past marijuana convictions and their families, women- and minority-owned businesses, and veterans, backed by a $200 million equity fund. It’s an ambitious bet that legalization can repair harm rather than just generate profit, and other states are paying close attention.